What "low margin" actually means and why it matters
Most pharmacy owners track average gross profit per script as a single number. They see "$15 per fill" on their P&L and think things are fine. The problem with averages is that they hide a brutal distribution. That $15 average might be made up of 60 percent of fills earning $25, 30 percent earning $5, and 10 percent earning negative numbers. The pharmacy is profitable on average, but a chunk of the work happening every day is pure waste.
A "low margin script" is any fill where the gross profit is significantly below your target, or worse, negative. The exact threshold depends on your pharmacy and your contracts, but as a working definition: any fill where you make less than $5 in gross profit, or any fill with a negative margin, deserves a closer look. Negative margin fills should never just slide through. They are either a fixable mistake or a strategic loss you should be making consciously, not accidentally.
In 24 years of pharmacy operations and 40+ consulting engagements, I have not seen a single independent pharmacy where the bottom 20 percent of scripts by profitability did not have fixable problems. Every single one. The opportunity is real and it is hiding in your data right now.
The 10 reasons low margin happens
Low margin is not random. There are specific, recurring reasons it shows up, and each one has a different fix. Most low margin scripts fall into one of three categories: data hygiene problems in your dispensing system, billing process problems, or strategic dispensing decisions that need to be revisited. Here are the 10 most common reasons and what to do about each.
1. Wrong cost in your dispensing system
This one is the most common and the most embarrassing. Your dispensing system has the wrong acquisition cost loaded for the drug. Maybe the drug came from a different supplier than usual, maybe pricing changed and the system never updated, maybe it was set up wrong from the start. The PBM reimburses correctly based on real cost, but your system thinks you paid more than you did, so it shows the fill as low margin when it actually is not.
The fix: Pull your low margin report. For every drug on it, compare the cost in your system against the most recent invoice from the wholesaler. Where the system cost is higher than the actual cost, update it. The fill becomes properly profitable on paper without any operational change.
2. Wrong AWP in your dispensing system
Same problem, different field. The AWP listed in your dispensing system does not match the current published AWP. Reimbursement formulas are usually written as "AWP minus X percent," so when your AWP is wrong, your expected reimbursement looks wrong, which makes the fill look unprofitable when it actually is not.
The fix: Verify the AWP in your dispensing system against current published values. Most dispensing systems pull AWP automatically from drug pricing databases, but the auto-update sometimes fails or lags. If you find drugs with incorrect AWPs, update them and check whether the bigger problem is your data feed configuration.
3. Wrong package size in your dispensing system
Package size errors happen when the dispensing system thinks a bottle has 100 tablets but it actually has 90, or thinks a vial is 10mL when it is 20mL. Reimbursement is calculated per unit, so a wrong package size produces a wrong cost-per-unit and therefore a wrong margin calculation.
The fix: For every drug flagged as low margin, verify the package size in your system matches the actual package size from the manufacturer. The unit count should be the count per package as your system uses it.
4. Wrong metric size in your dispensing system
This one is subtle and bites a lot of pharmacies. Metric size is the amount per individual unit, separate from the package size. Take Lovenox injection as a classic example: a package contains 10 syringes, each syringe is 40mg/mL, and each syringe contains 0.4mL of solution. The package size is 10 (ten syringes), and the metric size is 4 (because 40mg/mL times 0.4mL equals 4 per syringe). Get either of those wrong and your system's margin calculation is going to be wrong.
The fix: For complex drugs like injectables, suspensions, and inhalers, manually verify both the package size and the metric size against the manufacturer's package insert. This is tedious work but it only has to be done once per drug, and these are usually high-cost items where getting the calculation right matters most.
5. Wrong price code submitted to insurance
Most third party plans accept multiple price codes (U&C, AWP, MAC, etc.) and the price you submit affects what they pay. Submit the wrong code and you may get reimbursed at a worse rate than you should have.
The fix: Audit which price code your dispensing system is submitting for each major plan. Compare the result against what the plan's contract actually allows. Some plans have specific submission requirements that are not obvious from the standard configuration. When in doubt, call the plan's pharmacy help desk and ask them to confirm which price code they expect.
6. Missing DAW code on the script
When a generic is available and a brand is dispensed, you need a Dispense As Written (DAW) code on the script for the PBM to pay you correctly. DAW 1 means the prescriber wrote the script as brand mandatory. DAW 2 means the patient requested brand. Without one of these codes, the PBM may reimburse the brand at the generic rate and the patient may end up with a higher copay, both of which look like a low margin fill or worse.
The fix: Train your team to flag any brand fill where a generic is available and verify the DAW code is correct before transmitting. If the script does not specify, get the prescriber to clarify. This is a workflow change more than a system change, but it has a meaningful impact on reimbursement accuracy.
7. Brand dispensed when generic should have been
This is related to #6 but it is its own problem. Sometimes a brand gets dispensed when a generic should have been the obvious choice, and the PBM reimburses at the generic rate (which is usually below the brand acquisition cost). The result is a guaranteed loss on the fill.
The fix: Set up your dispensing system to alert the technician any time a brand is being filled when a generic equivalent exists. The default should always be the generic unless there is a specific clinical or DAW reason to dispense brand. Make brand dispensing a deliberate decision, not an accident.
8. Bad acquisition cost (you are paying too much for the drug)
Sometimes the system is right and you actually are paying more than you should be. Your wholesaler has the drug priced higher than the secondary market or higher than another wholesaler in your buying group. The PBM reimburses based on the market average, and you are above the market.
The fix: Review your supplier mix for the drugs flagged. Compare prices across your primary wholesaler, your secondary wholesaler, secondary market sources like MatchRx, and any buying group programs you participate in. Sometimes a small change to your purchasing order sequence (which supplier the system tries first) makes a meaningful difference in margin.
9. AWP variance across manufacturers
Generic drugs have multiple manufacturers, and the AWP for the same drug can vary significantly between manufacturers. If your dispensing system is grabbing the lowest-AWP NDC by default, you might be getting reimbursed at a lower rate than if you dispensed a different manufacturer's version of the same drug.
The fix: For your highest-volume generic drugs, identify which manufacturer's NDC produces the highest reimbursement and configure your system to default to that NDC where possible. This is the same logic as the manufacturer switches in the NDC Optimization guide, just framed from the low margin angle.
10. PBM is paying less than acquisition cost
Sometimes the PBM is just wrong. Their MAC list is out of date, the drug is in a market shortage, or the price they are willing to pay is below what any pharmacy can actually buy the drug for. This is not your fault, and it is not always permanent.
The fix: Submit a MAC appeal to the PBM. Document the actual acquisition cost from your wholesaler invoice. Most state laws now require PBMs to update MAC pricing within a specific timeframe when an appeal demonstrates the MAC is below cost. If you are part of a PSAO, they will usually file MAC appeals on your behalf and are very effective at it. Use them. This is one of the highest-leverage things a PSAO does for its members.
11. None of the above worked: try a therapeutic alternative
If you have been through all 10 reasons above and the fill is still losing money, the drug itself is just unprofitable on this PBM contract. Your remaining option is a therapeutic interchange: working with the prescriber to switch the patient to a clinically equivalent drug that has better economics.
This is exactly the workflow covered in the NDC Optimization guide. Identify the alternative, verify it is clinically appropriate, contact the prescriber with a specific request, get a new prescription, dispense the new drug, document the interchange. Done well, this turns a money-losing fill into one of your most profitable fills.
Building a system to catch low margin scripts going forward
Fixing the historical problems is important, but the bigger win is preventing them from happening in the first place. Here is the system I recommend for keeping low margin under control on an ongoing basis.
Step 1: Decide what "low margin" means at your pharmacy
You cannot manage what you have not defined. Pick a specific dollar threshold or percentage threshold below which a fill counts as low margin and gets flagged for review. For most independents, $5 of gross profit per fill is a reasonable starting line, but you may want to go higher if your average GP per script is well above that.
Whatever threshold you pick, write it down and share it with your team. Everyone needs to know what counts.
Step 2: Assign a point person (or two)
Someone has to own this. It does not have to be one person doing all the work, but one person needs to be accountable for the low margin program. They run the report, they triage the findings, they coordinate fixes, they track progress. Without an owner, the program will not happen.
For a smaller pharmacy this is usually the owner or pharmacy manager. For a larger pharmacy you can delegate to a senior technician with the right access. Just pick someone.
Step 3: Set up an alert in your dispensing system
The best time to catch a low margin fill is at the moment of dispensing, before the patient leaves the counter. Most modern pharmacy management systems can be configured to fire an alert any time a fill is flagged as low margin, so the technician or pharmacist can take a closer look before the script is finalized. PioneerRx, for example, supports this through its trigger system. Other systems have similar features under different names.
Configure the alert to fire on any fill below your defined threshold. The alert does not have to stop the workflow; it just has to surface the information so someone can decide whether to dig in or let it pass.
Step 4: Use your PSAO for MAC appeals
If you are part of a PSAO and you are not using them for MAC appeals, you are leaving money on the table. PSAOs have dedicated teams that file appeals at scale, they understand the appeal processes for each major PBM, and they know which arguments tend to win. Your job is to identify the fills worth appealing. Their job is to actually file the appeals. Make sure your low margin tracking system feeds into your PSAO's appeal process.
Step 5: Use real data analytics tools
The manual approach to tracking low margin scripts works, but it does not scale. For most independent pharmacies, the volume of fills is too high for a human to review every flagged item every week. This is where data analytics tools become valuable. Tools that scan your dispensing data nightly, flag every low margin fill, categorize the likely cause, and surface the highest-impact fixes.
This is exactly what TheRxOS does, and it is what most modern pharmacy data analytics platforms (Amplicare, the Smart Dispense category in general) are built around. The right tool turns "I wish I knew which fills were unprofitable" into "here are the 47 fills from yesterday that need attention, sorted by total dollar impact."
Step 6: Track conversions
The last piece is measurement. For every low margin fill you address, track what you did and what the outcome was. Did you update the cost in the system? Did you win a MAC appeal? Did you successfully convert the patient to a therapeutic alternative? Did you eat the loss because the script was clinically necessary?
Tracking these outcomes does two things. First, it shows you which fixes are working so you can do more of them. Second, it builds a body of evidence about your pharmacy's improvements over time, which is useful for everything from PBM negotiations to acquisition due diligence to your own peace of mind that the work is producing results.
The mistakes I see most often
After consulting on dozens of low margin programs, here are the failure patterns I see over and over.
- Treating it as a one-time cleanup. Owners run the report once, fix what they find, feel good, and never run it again. Three months later the same problems are back because the underlying causes (data drift, wholesaler price changes, MAC updates) never stop.
- Only looking at negative margin fills. The negative margin fills are obvious, but the larger opportunity is in the bottom quartile of positive margin fills. A fill earning $2 of gross profit when it could earn $15 is technically positive, but it is still a leak.
- Skipping the data hygiene checks. Owners jump straight to "the PBM is screwing me" without first verifying that their own system has the right cost, AWP, package size, and metric size loaded. Half of low margin problems are self-inflicted from data quality issues.
- Not using their PSAO. The PSAO is sitting there, waiting to file appeals on your behalf, and most pharmacies never send them anything. If you are paying PSAO fees, get the value back.
- Pharmacist doing everything. The pharmacist should be approving therapeutic interchanges and reviewing edge cases, not running the daily low margin report and updating cost data in the system. Push the routine work to a trained technician.
- No tracking. The pharmacy does the work but never measures the impact. Six months later they cannot tell you whether the program is producing results, which makes it hard to justify continuing the discipline.
What this looks like when it is working
A pharmacy with a mature low margin script program looks like this: every morning, a technician runs the previous day's low margin report. Most days there are 5 to 15 flagged fills. The technician triages them in 20 minutes, fixing the data hygiene problems immediately and flagging the strategic ones for the pharmacist. The pharmacist reviews the strategic items in another 20 minutes during their morning routine. MAC appeals get bundled and sent to the PSAO weekly. Therapeutic interchanges get worked through with prescribers as part of the normal clinical workflow.
Over a quarter, this discipline typically recovers somewhere between $5,000 and $15,000 of gross profit for a typical 3,000-script-per-month independent pharmacy. Some pharmacies recover much more. The total time investment is maybe 5 hours a week.
That is the shape of a real low margin program. Not glamorous, not complicated, but consistently profitable in a way that nothing else in pharmacy operations quite matches. The hard part is not knowing what to do. The hard part is doing it every single week without letting it slip.